Novel therapeutic agents for osteosarcoma.
Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd floor, Bronx, NY 10467, USA. koday@montefiore.org
Kathleen
K
O'Day
Richard
R
Gorlick
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004164:Diphosphonates / Q000008:administration & dosage; D000077143:Docetaxel; D004285:Dogs; D016503:Drug Delivery Systems; D005493:Folic Acid Antagonists / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays; D055815:Young Adult; D000093542:Gemcitabine
D020533:Angiogenesis Inhibitors; D004164:Diphosphonates; D005493:Folic Acid Antagonists; D007155:Immunologic Factors; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D019275:Radiopharmaceuticals; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine